Juzimette

Metformin Hydrochloride and Sitagliptin, the active ingredient in Juzimette, is a biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycemic control. GNH USA supplies Juzimette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Juzimette combines metformin and sitagliptin to improve glycemic control in type 2 diabetes mellitus.

Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels. Adjunct to diet and exercise: enhances overall glycemic management when lifestyle measures alone are insufficient. Combination with other antidiabetics: provides additional glucose reduction when monotherapy does not achieve targets.

Juzimette may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, usually transient. - Abdominal discomfort: cramping or bloating. - Headache: mild tension‑type headache. - Mild hypoglycemia: especially when combined with insulin or sulfonylureas. - Metallic taste: occasional altered taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: profound low blood glucose requiring assistance. - Pancreatitis: acute inflammation of the pancreas. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or angioedema. - Renal impairment: worsening kidney function, especially in dehydration.

Before prescribing Juzimette, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Renal function assessment: evaluate eGFR before initiating and periodically thereafter. Liver disease monitoring: avoid in patients with significant hepatic impairment. Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia or severe infection. Pregnancy and lactation: use only if potential benefit justifies potential risk. Drug‑induced hypoglycemia: educate patients on recognizing low‑blood‑glucose symptoms. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Juzimette can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycemia. - Iodinated contrast media: may precipitate renal impairment with metformin. - Cimetidine: can raise metformin plasma concentrations. - Strong CYP3A4 inhibitors: may affect sitagliptin metabolism. - Alcohol abuse: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics: may alter renal clearance of metformin. - Beta‑blockers: can mask hypoglycemia symptoms. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - Warfarin: possible effect on INR, require closer monitoring. - Rifampin: may reduce sitagliptin exposure, affecting efficacy.